When asked how they might use the application in the future to connect with patients between visits, 71% (29/41) indicated they would send a check-in regarding a recent change in diabetes management (e.g., transitioning from basal/bolus to pump therapy), 41% (17/41) would send a check in on general wellness, and 46% (19/41) would review glucose data and provide recommendations on insulin dose adjustments. The gene discussed is INS; the disease is diabetes mellitus.